ORTEXORTEX News
Tracking UBSG? Get live short interest, options flow, and signals on ORTEX.Sign up free →
UB
Trader NoteUBSG

UBS Posts a Beat but Trades Below Where Insiders Sold

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 4 Nov 2026, 20:03

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

UBS Group AG delivered a blowout third quarter last week, yet the stock at CHF 39.47 remains well below the prices at which its own executives were selling shares just weeks earlier.

The Q3 print on October 28 produced a 2.2% one-day gain. Net profit of CHF 8.1 billion beat analyst expectations and was described as the strongest quarter since the Credit Suisse takeover. Despite that, the stock has gone essentially nowhere over the past month, down 0.2%, and dipped 0.8% on Tuesday. The gap tells a pointed story: insider sellers who exited in August and September at CHF 43 to CHF 44 got their pricing right. The largest single disposal, CHF 4.5 million at CHF 44.62 on September 4, now looks well-timed. Net insider selling over the 90 days to early September totalled CHF 15.5 million across six transactions, all sales, involving both executive board members and non-executive directors. No buying appears anywhere in the register.

The lending market offers no pushback on that bearish insider signal. Availability is essentially uncapped, with more than 2.6 billion shares available to borrow against minimal short interest. The cost to borrow is a modest 0.73%, up around 8% on the week and 15% over the past month but still well within normal territory for a large-cap bank. Short positioning carries almost no weight in the story here: there is no squeeze pressure, no meaningful borrow tightness, and no short-side catalyst of note. The ORTEX short score of 26.1, in the 91st percentile for short-score rank, reflects how little short-side stress the stock currently faces rather than any directional call.

The Street is more constructive than the price implies. The analyst consensus target is CHF 44.93, roughly 14% above Tuesday's close. That target was last updated on October 29, one day after the earnings beat, so it reflects the post-print picture. EPS momentum factor scores reinforce the bullish reading: 87th percentile over 30 days, 82nd over 90 days, and an 80th-percentile EPS surprise rank. The price-to-book ratio has edged up to 1.50 this week, recovering modestly from the lows of recent weeks, while the P/E of 11.2x has drifted down around half a turn over the past month. Valuation remains modest by global bank standards, which is part of the bull case. The FDIC call report data for UBS's US banking charters, published quarterly by the Federal Deposit Insurance Corporation, shows net loans and leases rising for nine consecutive quarters and total deposits up for five in a row, streaks that reflect balance-sheet momentum even if the dataset has not yet accumulated enough history to test whether it leads UBS's reported figures.

Among its closest peers, Deutsche Bank gained 5.5% on the week while Goldman Sachs fell 1.7% and DWS dropped 2.6%. UBS's 1.6% weekly gain sits in the middle of a mixed picture for the sector, neither a standout nor a laggard. The next scheduled earnings event is February 3, 2027, leaving 91 days for the market to work out whether the Q3 beat changes anything about its view of a stock that has spent the autumn trading well below where those with inside knowledge chose to sell.

Stocks in this article

See the live data behind this article on ORTEX.

Open UBSG on ORTEX →

How this article was generated

Generated
4 Nov 2026, 20:04
Data as of
4 Nov 2026, 20:03
Prompt version
v1.0
Data sources
Cost to borrowUtilizationEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.